Arena Pharma (ARNA) Misses Q2 EPS by 7626c

Arena Pharma (NASDAQ: ARNA) reported Q2 EPS of ($77.00), $76.26 worse than the analyst estimate of ($0.74). Revenue for the quarter came in at $6.5 million versus the consensus estimate of $5.52 million.

For earnings history and earnings-related data on Arena Pharma (ARNA) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
• La-Z-Boy (LZB) Misses Q1 EPS by 6c, Misses on Revenue; Offers Weak Q2 Revenue Guidance